CRISPR Therapeutics Director Simeon George Reports Disposal of Common Shares Worth $720,373.362

CRISPR Therapeutics director Simeon George sold 14,514 Common Shares on October 14, 2026, at $49.633 per share. He also exercised stock options for 30,000 Common Shares at $14 per share that day. Following the transactions, George directly owned 15,486 Common Shares and indirectly held 2,038,763 Common Shares. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CRISPR Therapeutics AG published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-424317), on October 16, 2026, and is solely responsible for the information contained therein. (C)